Recently, the FDA approved Kynamro (mipomersen sodium, Isis Pharmaceuticals, Carlsbad, CA) as a treatment for familial hypercholesterolemia.11,12 Kynamro, a DNA 10-mer with 2′-O-MOE-modified-5-mers at both ends, targets Apolipoprotein B (ApoB). This evidence concerns the gene APOB and familial hypercholesterolemia.